Expression of cyclin D1 proto-oncogene mRNA in primary meningiomas may contribute to tumorigenesis

International Journal of Oncology

Volumn 9, Issue 6, 1996, Pages 1213-1217

  Maxwell, Marius ^a,b,c   Galanopoulos, Theofanis ^b   Antoniades, Harry N ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

cell cycle; cyclins; meningioma; tumorigenesis

Indexed keywords

CYCLIN D1; MESSENGER RNA;

ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MENINGIOMA; PRIORITY JOURNAL; PROTO ONCOGENE;

EID: 0029852498     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.9.6.1213     Document Type: Article

References (45)

1. Bishop JM: Molecular themes in oncogenesis. Cell 64: 235-248, 1991.
2. Russell DS and Rubinstein LJ: Pathology of Tumors of the Nervous System. 5th edition, Williams & Wilkins, Baltimore, pp452-532, 1989.
3. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RA and Martuza RL: Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 62: 18-24, 1985.
4. Larson JJ, Tew JM, Simon M and Menon AG: Evidence for clonal spread in the development of multiple meningiomas. J Neurosurg 83: 705-709, 1996.
5. Wang J-L, Nister M, Hermansson M, Westermark B and Ponten J: Expression of PDGF β-receptors in human meningioma cells. Int J Cancer 46: 772-778, 1990.
6. Maxwell M, Galanopoulos T, Antoniades HN: Coexpression of EGF receptor and TGFα mRNA and protein occurs in primary meningiomas. Int J Oncol 9: 917-922, 1996.
7. Linggood RM, Hsu DW, Efird JT and Pardo FS: TGFα expression in meningioma - tumor progression and therapeutic response. J Neuro-Oncol 26: 45-51, 1995.
8. Maxwell M, Galanopoulos T, Hedley-White ET, Black P and Antoniades HN: Human meningiomas coexpress platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products. Int J Cancer 46: 16-21, 1990.
9. Antoniades HN, Galanopoulos T, Neville-Golden J and Maxwell M: Expression of insulin-like growth factors I and II and their receptor mRNA's in primary human astrocytomas and meningiomas; in vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer 50: 215-222, 1992.
10. Carstens C, Messe E, Zang KD and Blin N: Human KRAS oncogene expression in meningioma. Cancer Lett 43: 37-41, 1988.
11. Zhao J-F and Sharma S: Expression of the ROS1 oncogene for tyrosine receptor kinase in adult human meningiomas. Cancer Genet Cytogenet 83: 148-154, 1995.
12. Mehta D, Khatib R and Patel S: Carcinoma of the breast and meningioma: Association and management. Cancer 51: 1937-1940, 1983.
13. Maxwell M, Galanopoulos T, Neville-Golden J and Antoniades HN: Expression of androgen and progesterone receptors in primary human meningiomas. J Neurosurg 78: 456-462, 1993.
14. Mulder E, van Loon D and de Boer W: Mechanism of androgen action: recent observations on the domain structure of androgen receptors and the induction of EGF-receptors by androgens in prostate tumor cells. J Steroid Biochem Mol Biol 32: 151-156, 1989.
15. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, Delattre O, Thomas G, Nordenskjold M, Collins VP, Dumanski JP and Rouleau GA: Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nature Genet 6: 180-184, 1994.
16. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Zuang K, Demcuk S, Desmaze C, Plougastel B, Pulst SM, Lenoir G, Bijlsma E, Fahsold R, Dumanski J, de Jong P, Parry D, Eldrige R, Aurias A, Delattre O and Thomas G: Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 363: 515-521, 1993.
17. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon A, Pulaski K, Haase VH, Ambrose CM, Munroe D, Bove C, Haines JL, Martuza RL, MacDonald ME, Seizinger BR, Short MP, Buckler AJ and Gusella JF: A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72: 791-800, 1993.
18. Pulst SM, Rouleau GA, Marineau C, Fain P and Sieb JP: Familial meningioma is not allelic to neurofibromatosis 2. Neurology 43: 2096-2098, 1993.
19. Rempel SA, Schwechheimer K, Davis RL, Cavenee WK and Rosenblum ML: Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. Cancer Res 53: 2386-2392, 1993.
20. Lindblom A, Ruttledge M, Collins VP, Nordenskjold M, Dumanski JP: Chromosomal deletions in anaplastic meningiomas suggest multiple regions outside chromosome 22 as important in tumor progression. Int J Cancer 56: 354-357, 1994.
21. Wang J-L, Zhang Z-J, Hartman M, Smits A, Westermark B, Muhr C and Nister M: Detection of TP53 gene mutation in human meningiomas: a study using immunohistochemistry, polymerase chain reaction/single-strand conformation polymorphism and DNA sequencing techniques on paraffin-embedded samples. Int J Cancer 64: 223-228, 1995.
22. Lekanne-Deprez RH, Riegman PHJ, Groen NA, Warringer UL, van Biezen NA, Molijn AC, Bootsma D, deJonge PJ, Menon AG, Kley NA, Seizinger BR and Zwarthoff EC: Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced translocation in a meningioma. Oncogene 10: 1521-1528, 1995.
23. Sherr CJ: Mammalian G1 cyclins. Cell 73: 1059-1065, 1993.
24. Li Y, Nichols MA, Shay JW and Xiong Y: Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 54: 6078-6082, 1994.
25. Jiang W, Kahn SM, Tomita N, Zhang Z-F, Lu SH and Weinstein BN: Amplification and expression of the human cyclin D1 gene in esophageal cancer. Cancer Res 52: 2980-2983, 1992.
26. Lammie AC, Fantl V, Smith R, Schuuring E, Brookes S, Michelides R, Dickson C, Arnold A and Peters G: D11S287, a putative oncogene on chromosome 11q13 is amplified and expressed in squamous cell and mammary carcinomas and is linked to BCL-1. Oncogene 6: 439-444, 1991.
27. Bartkova J, Lukas J, Muller H, Strauss M, Gusterson B and Bartek J: Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 55: 949-956, 1995.
28. Xiong Y, Connolly T, Futcher B and Beach D: Human D-type cyclin. Cell 65: 691-699, 1991.
29. Maxwell M, Galanopoulos T and Antoniades HN: Cell cycle regulator cyclin D1 mRNA and protein overexpression occurs in primary malignant gliomas. Int J Oncol 9: 493-497, 1996.
30. Hunter T and Pines J: Cyclins and Cancer. Mini-review. Cell 66: 1071-1074, 1991.
31. Ponte P, Ng SY and Engel J: Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human β-actin cDNA. Nucleic Acid Res 12: 1687-1696, 1984.
32. Williams BO, Remington L, Albert DM, et al: Cooperative tumorigenic effects of germline mutations in Rb and p53. Nature Genet 7: 480-484, 1994.
33. Rb phosphorylation during mitogenic stimulation of G1-arrested human breast cancer cells. Oncogene 12: 2315-2324, 1996.
34. Lebwohl DE, Muise-Helmericks R, Sepp-Lorenzino L, Serve S, Timaul M, Bol R, Borgen P and Rosen M: A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line. Oncogene 9: 1925-1929, 1994.
35. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE and Skolnick NH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994.
36. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA: Deletions of the cyclin-dependent kinase 4-inhibitor gene in multiple human cancers. Nature 368: 753-756, 1994.
37. Schmidt EE, Ichimura K and Reifenberger G: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54: 6321-6324, 1994.
38. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DL and Steeg PS: Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Med 12: 1-4, 1995.
39. Hsu DW, Pardo FS, Efird JD, Linggood RM and Hedley-Whyte ET: Prognostic significance of proliferative indices in meningiomas. J Neuropath Exp Neurol 53: 247-255, 1994.
40. Cobb MA, Hussain M, Andersen BJ and Al-Mefty O: Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma. J Neurosurg 84: 85-91, 1996.
41. Shivji MKK, Kenny MK and Wood RD: Proliferating cell nuclear antigen is required for DNA excision repair. Cell 69: 367-374, 1992.
42. Morris GF and Mathews MB: Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem 264: 13856-13864, 1989.
43. Xiong Y, Zhang H and Beach D: D-type cyclins associated with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71: 505-514, 1992.
44. Hsu DW, Hakim F and Biller BMK: Significance of proliferating cell nuclear antigen in predicting pituitary adenoma recurrence. J Neurosurg 78: 753-761, 1993.
45. Zulch KJ: Histological typing of tumors of the central nervous system. International Histological Classification of Tumors. No. 21. World Health Organization, Geneva, 1979.